Naproxen Sodium 220mg
NDC Package 53329-678-30
Package Information
Naproxen Sodium 220mg is a . Marketed by Medline Industries, Lp, this product is identified by NDC 53329-678 and is authorized under FDA application ANDA091353.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 53329 - Medline Industries, Lp
- 53329-678 - Naproxen Sodium 220mg
- 53329-678-30 - 100 TABLET in 1 BOTTLE
- 53329-678 - Naproxen Sodium 220mg
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 53329-678-30 identifies a specific commercial package of 100 tablet in 1 bottle of Naproxen Sodium 220mg, labeled by Medline Industries, Lp. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Medline Industries, Lp on March 07, 2018. The current certification is valid through May 31, 2022.
How is this Medline Industries, Lp product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 53329067830. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.